4D Molecular Therapeutics LLC logo

4D Molecular Therapeutics LLC

4D Molecular Therapeutics LLC (4DMT) is a biopharmaceutical company, design and develop transformative gene therapy products to create adeno-associated virus variants for the treatment of Neurological disorders.

4DMT discovery technology was originally developed over 15 years by, co-Founder David Schaffer at the University of California, Berkeley, its therapeutics is based in the QB3@953 and JLABS laboratories in the Mission Bay area of San Francisco.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.4dmoleculartherapeutics.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
5980 Horton St. Suite 460, CA 94608
Emeryville
United States
Email
Contact Number
+1 510-505-2680
+1 412-848-3938

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/4d-molecular-therapeutics-llc” connections=”true” suffix=””]

4DMTs Therapeutic Vector Evolution discovery platform allows for the generation of gene vectors that are optimized for efficient gene delivery and uptake, tissue specificity, and evasion of pre-existing antibodies present in most patients.

In Jan, 2014, uniQure B.V., and 4DMT signed a collaboration & license agreement under which uniQure gains an exclusive access to 4Ds adeno-associated viral vector discovery & optimization technology for gene delivery to central nervous system and liver. No financial details were disclosed.

In Apr 2015, 4DMT and Roche signs a collaboration agreement for Gene Therapy Vector Discovery and Product Development for indications with high unmet medical need. Financial details on collaboration were not disclosed.

In Feb 2016, 4DMT and Choroideremia Research Foundation partners to develop Gene Therapy treatment for Choroideremia. Under the terms, CRF will provide 4DMT funding to deploy its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to create and optimize a proprietary AAV vector for intravitreal delivery to the retina.

In 2017, 4DMT received $3 M funding from funding from Cystic Fibrosis Foundation Therapeutics Inc.